Correlating cerebrospinal (CSF) dopamine transporter (DAT) levels with the regional brain glucose metabolism in AD patients revealed positive correlations, suggesting a potentially less-advanced disease status. The gene discussed is SLC6A3; the disease is Alzheimer disease.